{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:26Z","timestamp":1791995666560,"version":"4.4.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Daiichi Sankyo. In July 2020"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Daiichi Sankyo for datopotamab deruxtecan","award":["Dato-DXd; DS-1062"],"award-info":[{"award-number":["Dato-DXd; DS-1062"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate comprised of a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2, a protein that is broadly expressed in several types of solid tumors. Dato-DXd demonstrated statistically significant improvement in median progression-free survival (mPFS) over docetaxel in patients with previously treated metastatic non-small cell lung cancer (mNSCLC) and over the investigator\u2019s choice of chemotherapy in patients with previously treated post-endocrine therapy hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative metastatic breast cancer (mBC). Dato-DXd also demonstrated a distinct safety profile in both trials. The successful implementation of any new anticancer therapy requires learning how to prevent, monitor, and manage treatment-related adverse events (AE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Perspectives were gathered from 4 medical oncologists, 2 nursing professionals, and 1 pharmacist with experience using Dato-DXd in either mNSCLC or mBC across several US practices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Here, we share practical insights and management and treatment of key AEs from Dato-DXd, including oral mucositis\/stomatitis, nausea and vomiting, ocular surface events, and interstitial lung disease garnered from the multidisciplinary team of health care professionals experienced in treating patients with Dato-DXd.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sharing experiences and institutional approaches from real-world clinical practices and multidisciplinary teams who treat patients with Dato-DXd may help provide a better patient experience and improved outcomes to a broader population of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf225","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:14:40Z","timestamp":1752837280000},"source":"Crossref","is-referenced-by-count":13,"title":["Datopotamab deruxtecan\u2013associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-4352","authenticated-orcid":false,"given":"Aaron","family":"Lisberg","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at University of California Los Angeles , Santa Monica, CA 90404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A","family":"Huppert","sequence":"additional","affiliation":[{"name":"University of California San Francisco Helen Diller Family Comprehensive Cancer Center , San Francisco, CA 94143-0981,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8360","authenticated-orcid":false,"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Department of Oncology , Bronx, NY 10461,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Ledezma","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at University of California Los Angeles , Santa Monica, CA 90404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Soto-Romano","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A","family":"Traina","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025091915391830300_oyaf225-B1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"2025091915391830300_oyaf225-B2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"2025091915391830300_oyaf225-B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fmed.2017.00013","article-title":"Second-line treatment of non-small cell lung cancer: clinical, pathological, and molecular aspects of nintedanib","volume":"4","author":"Corrales","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2025091915391830300_oyaf225-B4","author":"American Cancer Society","year":"2024"},{"key":"2025091915391830300_oyaf225-B5","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.3390\/cancers13215397","article-title":"Resistance mechanisms to combined CDK4\/6 inhibitors and endocrine therapy in ER+\/HER2\u2212 advanced breast cancer: biomarkers and potential novel treatment strategies","volume":"13","author":"Al-Qasem","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025091915391830300_oyaf225-B6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"on behalf of the EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"2025091915391830300_oyaf225-B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4137\/BCBCR.S39615","article-title":"Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer","volume":"10","author":"Twelves","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"key":"2025091915391830300_oyaf225-B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.breast.2019.07.006","article-title":"Metronomic chemotherapy for advanced breast cancer patients in the real world practice: final results of the VICTOR-6 study","volume":"48","author":"Cazzaniga","year":"2019","journal-title":"Breast"},{"key":"2025091915391830300_oyaf225-B9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"\u00adAntibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025091915391830300_oyaf225-B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2025091915391830300_oyaf225-B11","year":"2025"},{"key":"2025091915391830300_oyaf225-B12","year":"2025"},{"key":"2025091915391830300_oyaf225-B13","year":"2025"},{"key":"2025091915391830300_oyaf225-B14","year":"2025"},{"key":"2025091915391830300_oyaf225-B15","year":"2024"},{"key":"2025091915391830300_oyaf225-B16","year":"2025"},{"key":"2025091915391830300_oyaf225-B17","doi-asserted-by":"crossref","first-page":"PD13-08","DOI":"10.1158\/1538-7445.SABCS22-PD13-08","article-title":"Abstract PD13-08: phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor\u2013positive\/HER2-negative breast cancer (BC)","volume":"83","author":"Meric-Bernstam","year":"2023","journal-title":"Cancer Res"},{"key":"2025091915391830300_oyaf225-B18","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-\u00adescalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091915391830300_oyaf225-B19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025091915391830300_oyaf225-B20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025091915391830300_oyaf225-B21","doi-asserted-by":"publisher","first-page":"S1630","DOI":"10.1016\/j.annonc.2024.10.656","article-title":"LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with \u00adpreviously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): a pooled analysis of TROPION-Lung01 and TROPION-\u00adLung05","volume":"35","author":"Ahn","year":"2024","journal-title":"Ann Oncol"},{"key":"2025091915391830300_oyaf225-B22","author":"Girard","year":"2024"},{"key":"2025091915391830300_oyaf225-B23"},{"key":"2025091915391830300_oyaf225-B24"},{"key":"2025091915391830300_oyaf225-B25"},{"key":"2025091915391830300_oyaf225-B26"},{"key":"2025091915391830300_oyaf225-B27"},{"key":"2025091915391830300_oyaf225-B28"},{"key":"2025091915391830300_oyaf225-B29"},{"key":"2025091915391830300_oyaf225-B30"},{"key":"2025091915391830300_oyaf225-B31"},{"key":"2025091915391830300_oyaf225-B32","author":"United States Food and Drug Administration"},{"key":"2025091915391830300_oyaf225-B33","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2025091915391830300_oyaf225-B34","author":"National Cancer Institute"},{"key":"2025091915391830300_oyaf225-B35","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.esmoop.2024.103479","article-title":"LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable\/metastatic HR+\/HER2\u2013 breast cancer (BC): additional safety analysis from TROPION-Breast01","volume":"9","author":"Jhaveri","year":"2024","journal-title":"ESMO Open"},{"key":"2025091915391830300_oyaf225-B36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.annonc.2025.01.009","article-title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in \u00adpreviously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): final overall survival (OS) from the phase III TROPION-Breast01 trial","volume":"36","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"key":"2025091915391830300_oyaf225-B37"},{"key":"2025091915391830300_oyaf225-B38"},{"key":"2025091915391830300_oyaf225-B39","first-page":"462","article-title":"Magic mouthwash demystified","volume":"54","author":"Kravitz","year":"2020","journal-title":"J Clin Orthod"},{"key":"2025091915391830300_oyaf225-B40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-\u00adrelated stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025091915391830300_oyaf225-B41","doi-asserted-by":"publisher","first-page":"101896","DOI":"10.1016\/j.jebdp.2023.101896","article-title":"Efficacy and safety of a dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study","volume":"23","author":"Kuba","year":"2023","journal-title":"J Evid Based Dent Pract"},{"key":"2025091915391830300_oyaf225-B42","author":"Oncology Nursing Society"},{"key":"2025091915391830300_oyaf225-B43","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf031","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam","year":"2025","journal-title":"Oncologist"},{"key":"2025091915391830300_oyaf225-B44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clbc.2022.02.002","article-title":"Ocular toxicity in breast cancer management: manual for the oncologist","volume":"22","author":"Canino","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"2025091915391830300_oyaf225-B45","year":"2025"},{"key":"2025091915391830300_oyaf225-B46","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"2025091915391830300_oyaf225-B47","doi-asserted-by":"publisher","first-page":"8623","DOI":"10.1200\/JCO.2024.42.16_suppl.8623","article-title":"Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd)","volume":"42","author":"Sands","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025091915391830300_oyaf225-B48","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/oncolo\/oyac107","article-title":"Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan","volume":"27","author":"Bardia","year":"2022","journal-title":"Oncologist"},{"key":"2025091915391830300_oyaf225-B49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2025091915391830300_oyaf225-B50","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd\u2013related interstitial lung disease: the five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf225\/63834918\/oyaf225.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf225\/63834918\/oyaf225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf225\/63834918\/oyaf225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:39:22Z","timestamp":1758310762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf225\/8211180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf225","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,23]]},"article-number":"oyaf225"}}